Skip to content

Study on the effect of cognitive function and brain function in AD

Study on the effect of cognitive function and brain function in AD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099502
Enrollment
Unknown
Registered
2025-03-25
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease

Interventions

paying attention to mood and how to adjust emotions
and how to control basic diseases such as hypertension, diabetes and hyperlipidemia
Virtual reality intervention group:Use headset HTC Vive Pro, equipped with controller, static seat, use game scenes, such as cutting fruit cutting, whack-a-mole and other rich scenes for training. At
controlling risk factors of cognitive decline such as reducing sedentary, increasing exercise and interpersonal communication
paying attention to monitoring and adjusting sleep
Standard CARE group:Standard care, using standard care for Alzheimers disease (AD), covering medication, cognitive function training, physical exercise, psychological support and other contents. The c

Sponsors

The First Affiliated Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age: 55-90 years old; 2. Primary school education or above, visual and hearing barrier-free, can cooperate to complete the evaluation; 3. Overall cognitive function assessment: AD: MMSE: 15 points and 23 points, clinical AD rating scale (CDR)=0.5-1 score; 4. To participate in the study, obtained the consent of the guardian and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1.Have a history of neuropsychiatric diseases, such as cerebrovascular disease, depression, schizophrenia, drug dependence, intracranial tumor, refractory epilepsy, Parkinson's disease, normal pressure hydrocephalus, brain tumor and head trauma surgery, etc.; 2.Heart, liver, kidney, hematopoietic system and endocrine system diseases that seriously affect cognitive function; 3. The head magnetic resonance or CT has infarct lesions, microbleeding and space occupation lesions; 4. Are receiving other non-pharmacological interventions; Patients who met the above criteria were advised by the attending physician and recruited to participate in the study.

Design outcomes

Primary

MeasureTime frame
Overall cognitive function assessment;Multidimensional cognitive function assessment;

Secondary

MeasureTime frame
Imaging acquisition data;electroencephalogram data;Functional near-infrared spectroscopy (fNIRS);

Countries

China

Contacts

Public ContactYi Zhu

The First Affiliated Hospital of Nanjing Medical University

luckyzyx@163.com+86 137 0516 4030

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026